安科生物(300009) - 2017 Q3 - 季度财报

Financial Performance - Operating revenue for the current period reached CNY 284,731,027.84, a year-on-year increase of 31.17%[7] - Net profit attributable to shareholders for the current period was CNY 77,019,880.98, reflecting a growth of 36.86% year-on-year[7] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 74,564,652.43, up 45.95% year-on-year[7] - Basic earnings per share for the current period was CNY 0.1081, an increase of 33.46% compared to the same period last year[7] - The weighted average return on net assets was 5.23%, an increase of 0.76 percentage points year-on-year[7] - Total operating revenue for the third quarter reached ¥284,731,027.84, an increase from ¥217,068,636.69 in the previous period[43] - Net profit for the quarter was ¥77,314,515.51, up from ¥55,320,538.08 year-over-year, representing a growth of approximately 39.8%[44] - Earnings per share (EPS) for the quarter was ¥0.11, compared to ¥0.08 in the same period last year[45] - Total operating revenue for the current period reached ¥731,939,925.75, a significant increase of 28% compared to ¥572,175,487.67 in the previous period[50] - Net profit for the current period was ¥192,323,090.12, representing a 37% increase from ¥139,879,203.05 in the previous period[52] Asset and Equity Changes - Total assets increased by 6.29% to CNY 2,088,788,417.30 compared to the end of the previous year[7] - Net assets attributable to shareholders increased by 16.00% to CNY 1,576,481,499.65 compared to the end of the previous year[7] - Current assets rose to CNY 615,639,480.62, up from CNY 564,089,577.30, indicating an increase of about 9.1%[35] - Total liabilities decreased to CNY 434,224,394.19 from CNY 539,043,861.81, a reduction of approximately 19.5%[37] - Shareholders' equity increased to CNY 1,654,564,023.11 from CNY 1,426,199,965.78, representing a growth of about 16%[38] - Total assets of the company reached ¥1,770,921,913.19, an increase from ¥1,609,959,418.95[44] - Total equity increased to ¥1,365,539,415.48 from ¥1,200,899,774.82, reflecting a growth of approximately 13.7%[44] Cash Flow and Investments - Cash flow from operating activities for the year-to-date was CNY 159,315,480.31, up 20.81% year-on-year[7] - Cash and cash equivalents decreased by 47.66% compared to the beginning of the year, primarily due to significant cash outflows for investment activities and dividend payments[20] - Net cash flow from investing activities increased by 59.87% compared to the same period last year, mainly due to significant cash inflows from subsidiaries and other operating units in the previous year[22] - Cash flow from financing activities resulted in a net outflow of ¥75,166,611.92, contrasting with a net inflow of ¥228,783,278.37 in the previous period[60] - The company reported a net cash increase of ¥27,001,745.76 for the period, compared to a decrease of ¥31,769,349.30 in the previous period[63] - Total cash inflow from operating activities was ¥400,188,419.23, compared to ¥334,476,572.36 in the previous period, marking an increase of about 19.6%[61] Shareholder Information - The total number of shareholders at the end of the reporting period was 41,701[11] - The largest shareholder, Song Lihua, holds 27.93% of the shares, with 198,982,926 shares, of which 149,237,195 are pledged[11] - Shareholders plan to reduce their holdings by a total of up to 500,000 shares within six months due to personal financial needs[27] Expense and Tax Changes - Sales expenses increased by 38.22% compared to the same period last year, mainly due to increased market expenditure to expand sales scale and additional sales expenses from the merger with Zhongde Meilian[22] - Income tax expenses increased by 35.15% year-on-year, mainly due to a corresponding increase in the current income tax expense amount resulting from the growth in total profit[21] - The company reported a tax expense of ¥12,796,141.29, up from ¥9,468,615.41 in the prior period[44] Other Financial Metrics - Cash flow from financing activities included cash dividends and interest payments totaling ¥82,173,277.99, compared to ¥63,969,323.26 in the previous period, an increase of approximately 28.4%[63] - Investment income rose to ¥14,681,330.22, compared to ¥5,032,061.02 in the previous period, marking a 192% increase[52] - The company reported a total profit of ¥224,452,746.32, up 37% from ¥163,652,932.38 in the previous period[52]